Drug Profile
KM 8094
Alternative Names: KM8094Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer Kyowa Kirin
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Gastric-cancer in Japan (IV)
- 26 Oct 2017 Preclinical trials in Gastric cancer in Japan (IV)
- 26 Oct 2017 Pharmacodynamics data from a preclinical study in Gastric cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2017)